Conclusions and Perspective
[111In-DTPA0]-octreotide is a radiopharmaceutical with a great potential for the visualization of SSTR positive tumors. The overall sensitivity of SRI to localize neuroendocrine tumors is high. In a number of neuroendocrine tumor types, inclusion of SRI in the localization or staging procedure may be very rewarding, either in terms of cost-effectiveness, patient management, or quality of life. The value of SRI in patients with other tumors, like breast cancer, malignant lymphomas, or in patients with granulomatous diseases, has to be established. The development of PRRT is expected to stimulate peptide receptor imaging.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Patel Y.C., Amherdt M., Orci L. Quantitative electron microscopic autoradiography of insulin, glucagon and somatostatin binding sites on islets. Science 1982; 217:1155–6.
Reubi J.C., Kvols L.K., Waser B., et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50:5969–77.
Sreedharan S.P., Kodama K.T., Peterson K.E., Goetzl E.J. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989; 264:949–53.
Reubi J.C., Waser B., Vanhagen M., et al. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Canc 1992; 50:895–900.
Van Uden A., Steinmeijer M.V.J., De Swart J., et al. Imaging with octreoscan: haste makes waste. Eur J Nucl Med 1999; 26:1022.
Reubi J.C., Horisberger U., Studer U.E., Wascr B., Laissue JA. Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J Clin Endocrinol Metab 1993; 77:1323–28.
Gibril F., Reynolds J.C., Chen C.C., et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999; 40:539–53.
Plockinger U., Reichel M., Fett U., Saeger W., Quabbe H.J. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994; 79:1416–23.
Legovini P., De Menis E., Billed D., et al. 111 Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients. J Endocrinol Invest 1997; 20:424–8.
Oppizzi G., Cozzi R., Dallabonzana D., et al. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors. J Endocrinol Invest 1998; 21:512–9.
Kwekkeboom D.J., de Herder W.W., Krenning E.P. Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest 1999; 22:80–8.
De Bruin T.W.A., Kwekkeboom D.J., Van’ t Verlaat J.W., et al. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 1992; 75:1310–7.
Merola B., Colao A., Ferone D., et al. Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. Horm Res 1993; 40:149–55.
Kwekkeboom D.J., Krenning E.P., Oei H.Y., van Eyck C.H.J., Lamberts S.W.J. Use of radiolabeled somatostatin to localize islet cell tumors. In: Mignon M., Jensen R.T., eds. Frontiers of gastro-intestinal research, Vol 23. Endocrine tumors of the pancreas. New York: Karger, 1995: pp 298–308.
Cadiot G., Lebtahi R., Sarda L., et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 1996; 111:845–54.
De Kerviler E., Cadiot G., Lebtahi R., Faraggi M., Le Guludec D., Mignon M. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. Eur J Nucl Med 1994; 21:1191–7.
Gibril F., Reynolds J.C., Doppman J.L., et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125:26–34.
Zimmer T., Stolzel U., Bader M., et al. Endoscopie ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996; 39:562–8.
Alexander H.R., Fraker D.L., Norton J.A., et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228:228–38.
Lunderquist A. Radiologie diagnosis of neuroendocrine tumors. Acta Oncol 1989; 28:371–2.
Doherty G.M., Doppman J.L., Shawker T.H., et al. Results of a prospective strategy to diagnose, localize, and resect insulinomas. Surgery 1991; 110:989–97.
Rösch T., Lightdale C.J., Botet J.F., et al. Localization of pancreatic endocrine tumors by endoscopie ultrasonography. N Engl J Med 1992; 326:1721–6.
Lebtahi R., Cadiot G., Sarda L., et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38:853–8.
Termanini B., Gibril F., Reynolds J.C., et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112:335–47.
Lamberts S.W.J., Hofland L.J., Van Koetsveld P.M., et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors. Consequences with regard to diagnosis, localisation and therapy. J Clin Endocrinol Metab 1990; 71:566–74.
Kwekkeboom D.J., Krenning E.P., Bakker W.H., et al. Somatostatin analogue scintigraphy in carcinoid tumors. Eur J Nucl Med 1993; 20:283–92.
Westlin J.E., Janson E.T., Arnberg H., Ahlstrom H., Oberg K., Nilsson S. Somatostatin receptor scintigraphy of carcinoid tumours using the [111 In-DTPA-D-Phel]-octreotide. Acta Oncol 1993; 32:783–6.
Schillaci O., Scopinaro F., Angeletti S., et al. SPECT improves accuracy of Somatostatin receptor scintigraphy in abdominal carcinoid tumors. J Nucl Med 1996; 37:1452–6.
Ahlman H., Wängberg B., Tisell L.E., Nilsson O., Fjälling M., Forssell-Aronsson E. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg 1994; 81:1144–9.
Kvols L.K., Moertel C.G., O’Connell M.J., et al. Treatment of the malignant carcinoid syndrome. N Eng J Med 1986; 315:663–6.
Kvols L.K. Medical oncology considerations in patients with metastatic neuroendocrine carcinomas. Semin Oncol 1994; 21(suppl 13):56–60.
Kwekkeboom D.J., Van Urk H., Pauw K.H., et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 1993; 34:873–8.
Kwekkeboom D.J., Reubi J.C., Lamberts S.W.J., et al. In vivo Somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993; 76:1413–7.
Tisell L.E., Ahlman H., Wängberg B., et al. Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg 1997; 84:543–7.
Berna L., Chico A., and Matias-Guiu X., et al. Use of Somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Eur J Nucl Med 1998; 25:1482–8.
Adams S., Baum R.P., Hertel A., Schumm-Draeger P.M., Usadel K.H., Hör G. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 1998; 25:1277–83.
Postema P.T.E., De Herder W.W., Reubi J.C., et al. Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 1996; 1(suppl):36–7.
Baudin E., Schlumberger M., Lumbroso J., Travagli J.P., Caillou B., Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 1996; 81:2541–4.
Gulec S.A., Serafini A.N., Sridhar K.S., et al. Somatostatin receptor expression in Hurthle cell cancer of the thyroid. J Nucl Med 1998; 39:243–5.
Kwekkeboom D.J., Kho G.S., Lamberts S.W., Reubi J.C., Laissue J.A., Krenning E.P. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994; 21:1106–13.
O’Byrne K.J., Ennis J.T., Freyne P.J., Clancy L.J., Prichard J.S., Carney D.N. Scintigraphic imaging of small-cell lung cancer with [111]pentetreotide, a radiolabelled Somatostatin analogue. Br J Cancer 1994; 69:762–6.
Bombardieri E., Crippa F., Cataldo I., et al. Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111n-DTPA octreotide scintigraphy. Eur J Cancer 1995; 31A: 184–8.
Berenger N., Moretti J.L., Boaziz C., Vigneron N., Morere J.F., Breau J.L. Somatostatin receptor imaging in small cell lung cancer. Eur J Cancer 1996; 32A:1429–31.
Reisinger I., Bohuslavitzki K.H., Brenner W., et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 1998; 39:224–7.
Kirsch C.M., von Pawel J., Grau I., Tatsch K. Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med 1994; 21:1318–25.
Kwekkeboom D.J., Lamberts S.W.J., Habbema J.D., Krenning E.P. Cost-effectiveness analysis of Somatostatin receptor scintigraphy. J Nucl Med 1996; 37:886–92.
Van Eijck C.H., Krenning E.P., Bootsma A., et al. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 1994; 343:640–3.
Van Hagen P.M., Krenning E.P., Reubi J.C., et al. Somatostatin analogue scintigraphy of malignant lymphomas. Br J Haemat 1993; 83:75–9.
Van den Anker-Lugtenburg P.J., Krenning E.P., Oei H.Y., et al. Somatostatin receptor scintigraphy in the initial staging of Hodgkin’s disease. Br J Haematol 1996; 93:96–103.
Hoefnagel C.A., Rankin E.M., Valdés Olmos R.A., Israëls S.P., Pavel S., Janssen A.G.M. Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide. Eur J Nucl Med 1994; 21:587–8.
Krenning E.P., Kwekkeboom D.J., Bakker W.H., et at. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr-3-]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716–31.
Tenenbaum F., Lumbroso J., Schlumberger M., et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995; 36:1–6.
De Herder W.W., Krenning E.P., Malchoff C.D., et al. Somatostatin receptor scintigraphy: its value in tumor localization in patients with the Cushing syndrome caused by ectopic cortictropin and/or CRH secretion. Am J Med 1994; 96:305–12.
Philipponneau M., Nocaudie M., Epelbaum J., et al. Somatostatin analogs for the localization and preoperativc treatment of an ACTH-secreting bronchial carcinoid tumor. J Clin Endocrinol Metab 1994; 78:20–4.
Weiss M., Yellin A., Husza’r M., Eisenstein Z., Bar-Zif J., Krausz Y. Localization of adrenocorticotropic hormone-secreting bronchial carcinoid tumor by somatostatin-receptor scintigraphy. Ann Intern Med 1994; 121:198–9.
Torpy D.J., Chen C.C., Mullen N., et al. Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab 1999; 84:1186–92.
Haldemann A.R., Rosier H., Barth A., et al. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability. J Nucl Med 1995; 36:403–10.
Schmidt M., Scheidhauer K., Luyken C., et al. Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 1998; 25:675–86.
Reubi J.C., Horisberger U., Lang W., Koper J.W., Braakman R., Lamberts S.W.J. Coincidence of EGF receptors and Somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 1989; 134;337–44.
Vanhagen P.M., Krenning E.P., Reubi J.C., et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med 1994; 21:497–502.
Postema P.T.E., Krenning E.P., Wijngaarde R., et al. [111In-DTPA-D-Phe1]-octrcotidc scintigraphy in thyroidaal and orbital Graves’ disease: a parameter for disease activity? J Clin Endocrinol Metab 1994; 79:1845–51.
Krassas G.E., Dumas A., Pontikides N., Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 1995; 42:571–80.
Kahaly G., Görges R., Diaz M., Hommel G., Bockisch A. Indium-111-pentetreotide in Graves’ disease. J Nucl Med 1998; 39:533–6.
Kwekkeboom D.J., Krenning E.P., Kho G.S., Breeman W.A.P., Van Hagen P.M. Octreotide scintigraphy in patients with sarcoidosis. Eur J Nucl Med 1998; 25:1284–92.
Lebtahi R., Crestani B., Belmaloug N., et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med 2001; 42:21–6.
Reubi J.C., Waser B., Friess H., Krenning E.P., Büchler M., Laissue J. Regulatory peptide receptors in goiters of the human thyroid. J Nucl Med 1997; 38(suppl):266P.
Gerding M.N., van der Zant F.M., van Royen E.A., et al. Octreotide-scintigraphy is a disease-activity parameter in Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 1999; 50:373–9.
Modlin I.M., Cornelius E., Lawton G.P. Use of an isotopic Somatostatin receptor probe to image gut endocrine tumors. Arch Surg 1995; 130:367–73.
Wangberg B., Forssell-Aronsson E., Tisell L.E., Nilsson O., Fjalling M., Ahlman H. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phel-octreotide. Br J Cancer 1996; 73:770–5.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science + Business Media, Inc.
About this chapter
Cite this chapter
Kwekkeboom, D.J., de Jong, M., Krenning, E.P. (2004). Somatostatin Receptor Imaging. In: Srikant, C.B. (eds) Somatostatin. Endocrine Updates, vol 24. Springer, Boston, MA. https://doi.org/10.1007/1-4020-8033-6_13
Download citation
DOI: https://doi.org/10.1007/1-4020-8033-6_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4020-7799-9
Online ISBN: 978-1-4020-8033-3
eBook Packages: Springer Book Archive